|
|
|
|
|
Personalized Approaches to the Treatment of Prostate Cancer
|
Kenneth J. Pienta, MD and James L. Gulley, MD, Ph.D.
Ken Pienta and James Gulley join Alicia Morgans and Neal Shore sharing in discussion on PSMA, PARP inhibitors, and genomic-based therapies in prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Targeted Radionuclide Therapy of Prostate Cancer
|
Wolfgang Weber, MD
Wolfgang Weber joins Phillip Koo to share his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment.
|
|
|
|
|
|
|
|
|
|
|
Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer
|
|
Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Implementation of Germline Testing for Prostate Cancer |
| Veda N. Giri, MD |
| Charles Ryan and Veda Giri discuss consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP inhibitors. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
|
| PSMA Radioligand Therapy: A New Modality Approaches
|
| Kenneth J. Pienta, MD
|
| Kenneth Pienta gives an overview of prostate-specific membrane antigen (PSMA) radioligand therapy. PSMA is a transmembrane carboxypeptidase highly expressed on prostate cancer cells. Its expression has been observed in more than 95% of prostate cancer tumors. There is a direct correlation between PSMA expression levels and tumor aggressiveness.
|
|
|
|
|
|
|
|
|
|
|
| Why Precision Matters: Implications of Genomic Analysis for mCRPC |
| James L. Gulley, MD, Ph.D. |
| At the 2020 Virtual American Urological Association annual meeting’s International Prostate Forum, Dr. James Gulley discussed implications of the genomic analysis for patients with metastatic castration-resistant prostate cancer and why precision medicine for these patients matters. |
|
|
|
|
|
| Panel Discussion: Genetic Testing: What the Urologist Needs to Know
|
| Leonard G. Gomella, MD; Kevin Loughlin, MD; Todd Morgan, MD; and Veda Giri, MD
|
| Drs. Gomella, Loughlin, Morgan, and Giri discuss what the urologist needs to know about genetic testing including basic concepts in genetic testing for prostate cancer, implementation of germline testing for prostate cancer data from the Philadelphia Prostate Cancer Consensus Conference in 2019, genetic testing in the urology clinic, and take-home messages for the urologist. |
|
|
|
|
|
|
|
|
|
|
|
